Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Phase 1 Suspended
36 enrolled
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Phase 1 Suspended
30 enrolled
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
Phase 1 Suspended
66 enrolled
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Phase 1 Suspended
33 enrolled
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1 Suspended
30 enrolled
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
Phase 1 Suspended
53 enrolled
Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
Phase 1 Suspended
30 enrolled
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
Phase 1 Suspended
42 enrolled
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
Phase 1 Suspended
6 enrolled
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
Phase 1 Suspended
12 enrolled
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
Phase 1 Suspended
42 enrolled
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
Phase 1 Suspended
50 enrolled
Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity
Phase 1 Suspended
70 enrolled
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
Phase 1 Suspended
56 enrolled
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Phase 1 Suspended
75 enrolled
Liver-NET1
Phase 1 Suspended
43 enrolled
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Phase 1 Suspended
24 enrolled
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Phase 1 Suspended
20 enrolled
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Phase 1 Suspended
38 enrolled
Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma
Phase 1 Suspended
8 enrolled
68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma
Phase 1 Suspended
24 enrolled
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Phase 1 Suspended
20 enrolled
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
Phase 1 Suspended
55 enrolled
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
Phase 1 Suspended
30 enrolled
CT0991
Phase 1 Suspended
24 enrolled
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
Phase 1 Suspended
120 enrolled
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Phase 1 Suspended
29 enrolled
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Suspended
20 enrolled
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)
Phase 1 Suspended
10 enrolled
Pilot Trial of Preop Partial Radiation in Breast Cancer Patients
Phase 1 Suspended
98 enrolled
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Phase 1 Suspended
12 enrolled
Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4
Phase 1 Suspended
20 enrolled
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
Phase 1 Suspended
67 enrolled
Phase I Study in Advanced Malignancies With 5-ALA
Phase 1 Suspended
130 enrolled
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
Phase 1 Suspended
30 enrolled
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
Phase 1 Suspended
71 enrolled
APL-102 Capsule in Patients With Advanced Solid Tumors
Phase 1 Suspended
30 enrolled
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Phase 1 Suspended
131 enrolled
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
Phase 1 Suspended
18 enrolled
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Phase 1 Suspended
40 enrolled
CCPO011
Phase 1 Suspended
10 enrolled
Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
Phase 1 Suspended
30 enrolled
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
Phase 1 Suspended
10 enrolled
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Phase 1 Suspended
32 enrolled
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
Phase 1 Suspended
135 enrolled
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Phase 1 Suspended
24 enrolled
DNX-2440 for Resectable Colorectal Liver Metastasis
Phase 1 Suspended
30 enrolled
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Phase 1 Suspended
79 enrolled
RIM
Phase 1 Suspended
24 enrolled
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Phase 1 Suspended
73 enrolled